Home
HelpTest Code LAB9306 Lymphoid Oncology DNA Analysis
Aliases
Somatic Testing
Special Collection Notes
Collect specimen according to standard operating procedure
Specimen Type
Whole Blood or Bone Marrow/Purple Top Tube (K2 EDTA). Tissue (Fresh Frozen, Paraffin Embedded (FFPE) or RPMI)
Processing Instructions
*Store and ship ambient. If transport is longer than 4 hours send refrigerated on cold pack.
*For frozen tissue please send on dry ice- ASAP
*Receipt within 24 hours of cutting or as soon as possible. Delays may impact nucleic acid quality.
Specimen Volume
Optimal Volume: 4.0 ml Minimum Volume: 0.5 ml Formalin-fixed, paraffin-embedded tissue block (preferred) or 10 micron unstained slides. (10 count).
Additional Notes
A paired non-tumor “normal” specimen may be submitted concurrently with the tumor specimen to allow for comparison and classification of variants as germline or somatic.
- Normal specimens may include blood or buccal swabs for solid tumors and fingernails for hematopoietic tumors.
- Normal specimens MUST be submitted at the same time as the tumor specimen to allow for paired analysis.
- Analysis of normal specimens is performed at no additional charge.
- The ordering clinician has the option to select for reporting of the germline/somatic status of variants at the time of tumor testing or to leave the status unreported until after review of variants identified in the tumor.
- The order for reporting of the germline/somatic status may be added at any time so long as the normal specimen was submitted at the same time as the tumor.
- The ordering clinician is responsible for obtaining patient consent for the reporting of germline variants.
TAT
21 days
Method
Next Generation Sequencing
CPT
81455
Performing Section
PRECISION DIAGNOSTICS
Purpose/Principle
This panel includes DNA analysis 134 genes that have been described in the diagnosis, prognosis, or treatment decision process for lymphoid neoplasms, including both B- and T-cell neoplasms, as well as both leukemias and lymphomas.
Detection of single nucleotide variants (SNVs), small indels and flanking intronic regions in the following genes:
ABL1,ABL2,ALK,ARID1A,ARID2,ASXL1,ATM,B2M,BCL11B,BCL2,BCL6,BCOR,BRAF,BTK,BTKCARD11,CCND1,CCND2,CCND3, CCR4,CCR7,CD58,CD79A,CD79B,CDK4,CDK6,CDKN1B,CDKN2A,CDKN2B,CHEK2,CIITA,CREBBP,CRLF2,CSF1R, CTNNB1,CXCL12,CXCR4,DDX3X,DNM2,DNMT3A,EBF1,EED,EP300,EPHA7,ETV6,EZH2,FAS,FASLG,FBXW7,FGFR1,FGFR3, FLT3,FOXO1,FOXP1,GATA3,GNA13,HRAS,ID3,IDH1,IDH2,IKZF1,IKZF3,IL7R,INO80,JAK1,JAK2,JAK3,JUNB,KDM6A, KIR3DL2,KLF2,KMT2A,KMT2C,KMT2D,KRAS,MAP2K1,MAPK1,MDM2,MEF2B,MTOR,MYC,MYCN,MYD88,NF1,NOTCH1, NOTCH2,NRAS,NT5C2,NTRK3,PAX5,PDGFRA,PDGFRB,PHF6,PIK3CA,PIK3R1,PIM1,PPM1D,PRDM1,PRPS1,PSMB5,PTEN, PTPN1,PTPN11,PTPRD,RB1,REL,RELN,RHOA,RUNX1,SETD2,SF3B1,SGK1,SH2B3,SMARCA4,SOCS1,STAT3,STAT5B, STAT6,TCF3,TENT5C,TERT,TET2,TET3,TLX1,TNFAIP3,TNFRSF10A,TNFRSF14,TP53,TP63,USP7,WHSC1,WT1,XPO1,ZEB1, ZMYM3